文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Development and validation of a gene expression tumour classifier for cancer of unknown primary.

作者信息

Tothill Richard W, Shi Fan, Paiman Lisa, Bedo Justin, Kowalczyk Adam, Mileshkin Linda, Buela Evangeline, Klupacs Robert, Bowtell David, Byron Keith

机构信息

1Peter MacCallum Cancer Centre, East Melbourne 2National (ICT) Australia, The University of Melbourne, Parkville 3Healthscope Pathology, Clayton 4Circadian Technologies Limited, Toorak 5The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 6The Department of Pathology, University of Melbourne, Parkville 7The Department of Biochemistry, University of Melbourne, Parkville, Vic, Australia.

出版信息

Pathology. 2015 Jan;47(1):7-12. doi: 10.1097/PAT.0000000000000194.


DOI:10.1097/PAT.0000000000000194
PMID:25485653
Abstract

Accurate identification of the primary tumour in cancer of unknown primary (CUP) is required for effective treatment selection and improved patient outcomes. The aim of this study was to develop and validate a gene expression tumour classifier and integrate it with histopathology to identify the likely site of origin in CUP.RNA was extracted from 450 formalin fixed, paraffin embedded samples of known origin comprising 18 tumour groups. Whole genome expression analysis was performed using a bead-based array. Classification of the tumours made use of a binary support vector machine, together with recursive feature elimination. A hierarchical tumour classifier was developed and incorporated with conventional histopathology to identify the origins of metastatic tumours.The classifier demonstrated an accuracy of 88% for correctly predicting the tumour type on a validation set of known tumours (n = 94). For CUP samples (n = 49) having a final clinical diagnosis, the classifier improved the accuracy of histology alone for both single and multiple predictions. Furthermore, where histology alone could not suggest any specific diagnosis, the classifier was able to correctly predict the primary site of origin.We demonstrate the integration of gene expression profiling with conventional histopathology to aid the investigation of CUP.

摘要

相似文献

[1]
Development and validation of a gene expression tumour classifier for cancer of unknown primary.

Pathology. 2015-1

[2]
Efficient identification of miRNAs for classification of tumor origin.

J Mol Diagn. 2013-11-5

[3]
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Cancer Res. 2005-5-15

[4]
An integrated tool for determining the primary origin site of metastatic tumours.

J Clin Pathol. 2017-12-16

[5]
Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.

Oncogene. 2010-5-31

[6]
Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

J Pathol. 2013-12

[7]
Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.

Int J Cancer. 2009-9-15

[8]
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

J Clin Oncol. 2008-9-20

[9]
[Molecular diagnostic methods designed for clinical approach to cancer of unknown origin].

Gan To Kagaku Ryoho. 2009-6

[10]
Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.

Diagn Pathol. 2010-1-13

引用本文的文献

[1]
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.

Nat Rev Clin Oncol. 2025-8-4

[2]
GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling.

Cancer Res Commun. 2025-9-1

[3]
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.

Nat Commun. 2025-5-20

[4]
Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine.

MedComm (2020). 2025-4-16

[5]
Tracing unknown tumor origins with a biological-pathway-based transformer model.

Cell Rep Methods. 2024-6-17

[6]
A review on trends in development and translation of omics signatures in cancer.

Comput Struct Biotechnol J. 2024-2-3

[7]
New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.

Brief Bioinform. 2024-1-22

[8]
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.

J Pathol. 2023-1

[9]
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.

Nat Commun. 2022-8-2

[10]
Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary.

Psychooncology. 2022-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索